Почетна › Srpastoćelijska bolest › Тексас
Kliničke studije za Srpastoćelijska bolest u državi Тексас
13 studija za Srpastoćelijska bolest traži učesnike na lokacijama u državi Тексас.
Gradovi u državi Тексас
Zvanični tekst studije (na engleskom)
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
- Texas Childrens Cancer and Hematology Center, Houston
- U of TX Health Science Ct, Houston
Тражи се учесникФаза 3
Узраст од 12 до 100 · Оба пола · Ажурирано 10. 11. 2026. · NCT06439082Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
- UT Physicians Comprehensive Adult Sickle Cell Center, Houston
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT07224360A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD)
- University of Texas Health Science Center at Houston, Houston
Тражи се учесникФаза 3
Узраст 12 и старији · Оба пола · Ажурирано 28. 10. 2026. · NCT07656415A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease
- UT Health Science Center, Houston
Тражи се учесникФаза 1/2Здраве особе су добродошле
Узраст од 12 до 55 · Оба пола · Ажурирано 27. 10. 2026. · NCT06546670The Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease
- Baylor College of Medicine- Site Number : 8400055, Houston
- UT Physicians - Memorial Hermann- Site Number : 8400052, Houston
Тражи се учесникФаза 3
Узраст од 10 до 65 · Оба пола · Ажурирано 15. 10. 2026. · NCT06975865A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia
- Texas Children's Hospital_Houston, Houston
- UT Health University of Texas, Houston
Тражи се учесникФаза 3
Узраст 2 и старији · Оба пола · Ажурирано 18. 9. 2026. · NCT06609226A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
- UT Health University of Texas, Houston
Тражи се учесникФаза 3
Узраст 12 и старији · Оба пола · Ажурирано 17. 9. 2026. · NCT06612268ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
- Children's Blood and Cancer Center of Central Texas, Austin
- North Texas Hemophilia and Thrombosis Program - Pediatric Program / Center for Cancer & Blood Disorders, Dallas
- North Texas Comprehensive Hemophilia Treatment Center, Dallas
- и још 3
Тражи се учесникОпсервациона студија
Сви узрасти · Оба пола · Ажурирано 17. 8. 2026. · NCT04398628Comparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients With Sickle Cell Disease
- Texas Children's Hopsital (NT-DMT), Houston
- Texas Children's Hospital (MRD-HCT), Houston
- UT San Antonio (NT-DMT), San Antonio
Тражи се учесникОпсервациона студија
Узраст од 3 до 20 · Оба пола · Ажурирано 4. 6. 2026. · NCT06941389Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease
- Site # 8400004, Houston
Тражи се учесникФаза 3
Узраст од 2 до 17 · Оба пола · Ажурирано 15. 4. 2026. · NCT07247188Sickle Cell Kidney Biorepository
- Parkland Memorial Hospital, Dallas
- University of Texas Southwestern Medical Center, Dallas
Тражи се учесникОпсервациона студијаЗдраве особе су добродошле
Узраст од 18 до 65 · Оба пола · Ажурирано 13. 4. 2026. · NCT07064174Zinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial
- Baylor College of Medicine, Houston
Тражи се учесникФаза 2
Узраст од 15 до 40 · Оба пола · Ажурирано 13. 3. 2026. · NCT06260891Recruitment and Engagement in Care to Impact Practice Enhancement (RECIPE) for Sickle Cell Disease
- University of Texas at Houston, Houston
Тражи се учесникОпсервациона студија
Узраст 18 и старији · Оба пола · Ажурирано 22. 6. 2025. · NCT06385886Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.